Polishing the "pig" business card, "chain" out of new kinetic energy. On April 16, the third live broadcast of Hubei Juli pig industry chain brand building financial media came to Wuhan East Lake High-tech Development Zone, and the event was broadcast live through Xinhua News Agency's on-site cloud, cloud on the ridge, ridge on the ridge video number, Douyin account, Kuaishou account and other platforms, with a total of 1.155 million viewers.
This year's No. 1 central document pointed out that "it is necessary to strengthen the construction of ecological civilization in rural areas." Promote the reduction of the use of veterinary antimicrobials. Strengthen the prevention and control of major animal diseases and key zoonotic diseases. "Animal disease prevention and control is the first line of defense for public health safety, and compulsory immunization against animal diseases can effectively build a solid animal epidemic prevention barrier.
Today, let's follow the host Zhang Yanan into the field of animal protection in the upstream of the pig industry chain, and see how Hubei provides a strong guarantee for the stable and healthy development of the pig industry through scientific and technological innovation.
The first stop of the live broadcast: Sinopharm Animal Health Co., Ltd
Founded in 1971, Sinopharm Animal Health Co., Ltd. (hereinafter referred to as "Sinopharm Animal Health Company") is a national high-tech enterprise specializing in the research and development, production, sales and technical services of animal health products, and is the backbone enterprise of China National Biotechnology Co., Ltd., a subsidiary of China National Pharmaceutical Group, one of the world's top 500 companies.
Sun Wen, deputy secretary of the Party Committee and general manager of Sinopharm Animal Protection Company, introduced that at present, the company has more than 20 production lines in Wuhan Optics Valley and Yangzhou Hanjiang, supporting the construction of intelligent laboratory animal bases, and has passed the national new version of veterinary drug GMP certification, ISO three system certification, veterinary drug GCP certification and CNAS laboratory certification, with an annual production capacity of more than 10 billion feathers (heads), and is a designated manufacturer of national major animal disease vaccines.
It is understood that Sinopharm Animal Protection Company has presided over the research and development of a number of genetically engineered animal vaccines, among which, the self-developed porcine circovirus type 2 baculovirus vector inactivated vaccine (CP08 strain) is the first virus-like particle (VLPs) vaccine in China, and the market share of the product has ranked first in the country for many years after its launch. The product broke the international monopoly, realized independent research and development and independent production, and effectively reduced the price of this type of vaccine, so that breeding enterprises can reduce costs and get benefits.
R&D and production are two important links in the enterprise, which directly affect the competitiveness and development of the enterprise. Yu Minghua, manager of the production department of Sinopharm Health Care Company, introduced that the entire vaccine production workshop covers an area of 7,123 square meters and is equipped with 4 production lines, and the overall level is among the top five in the country.
Spring is the peak season for vaccine demand, Yu Minghua said that in the first quarter of this year, compared with the same period in 2023, the vaccine output has increased by 15%, and the product quality pass rate is 100%, and new breakthroughs have been made in process innovation, product quality, cost reduction and efficiency increase, and product achievement transformation.
The second stop of the live broadcast: Wuhan Huisheng Biotechnology Co., Ltd
In addition to Sinopharm Animal Health Company, there are many scientific and technological innovation enterprises in Wuhan. No, the host's second stop came to Wuhan Huisheng Biotechnology Co., Ltd. (hereinafter referred to as "Huisheng Bio").
Founded in 2002 and headquartered in Wuhan Airport Economic and Technological Development Zone, Huisheng Biotech is a high-tech enterprise focusing on the field of animal health care, covering veterinary drug preparations, synthetic APIs, microbial fermentation, Chinese veterinary drug extraction, veterinary drug chain and other business sectors, integrating product development, production and sales. It has three technical research centers and three wholly-owned subsidiaries, basically covering the entire veterinary drug industry chain.
Huisheng Biotech has been successively recognized as "National Key Leading Enterprise of Agricultural Industrialization", "National Agricultural and Rural Informatization Demonstration Base", "National Intellectual Property Advantage Enterprise", "Hubei Innovative Pilot Enterprise", "Hubei Provincial Technological Innovation Demonstration Enterprise", "Hubei Province Specialized and Special New Little Giant Enterprise", "Hubei Province Pillar Industry Segmentation Invisible Champion Cultivation Enterprise", "China Animal Protection Association Vice Chairman Unit", and is the first enterprise in Hubei Province to win the "China Famous Trademark" in this industry.
On August 24, 2020, Huisheng Biotech was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange, which is the first and only listed company in China with veterinary preparations as its main business. According to the China Veterinary Drug Association, Huisheng Bio's sales currently rank second in the field of veterinary chemical preparations in China.
Scientific and technological innovation is the source of enterprise development, Li Shuo, deputy general manager of Huisheng Biology, pointed out that the company is focusing on solving the pain points of the industry (African swine fever, PRRS, diarrhea and other major diseases) and weak links (pets, aquatic products and other therapeutic drugs), the formation of scientific research and technological achievements, to accelerate the breakthrough of key core technologies, enhance the overall innovation ability of the industry, to solve the constraints of industrial development of the "neck" technology has an important supporting role.
At present, Huisheng Biotech has established long-term and stable cooperative relations with many universities such as China Agricultural University, Huazhong Agricultural University, Wuhan University, South China Agricultural University, etc., and has carried out in-depth cooperation in scientific research projects. As of March 2024, the company has signed more than 70 scientific research projects with major universities and institutes in China.
What are the achievements in the development of Hubei pig industry chain?
What are the unique experiences and practices of other places?
We polish the business card of "pig" and "chain" to create new kinetic energy——
Hubei Juli pig industry chain brand building
The live broadcast of the integrated media will continue
Stay tuned!
Edited | Cheng Tianjie
Editor| Qiu Hongyue
Producer | Xiao Peng